3SBio Inc. Announces Unaudited Second Quarter 20...(nterest income 2454 ...),Health

Date:8/11/2009

nterest income 2,454 359 Grant income 93 14 Net realized gain on available-for-sale securities -- -- Others 1,681 246 Total other income, net 4,228 619 Income before income tax expense 31,366 4,592 Income tax expense (4,670) (684) Net income 26,696 3,908 Net income per share: Basic and diluted 0.18 0.03 Basic weighted average number of shares outstanding 150,586,455 150,586,455 Effect of dilutive potential shares 132,858 132,858 Diluted weighted average number of shares outstanding 150,719,313 150,719,313 Net income per ADS: Basic and diluted 1.24 0.18 Basic weighted average number of ADSs outstanding 21,512,351 21,512,351 Effect of dilutive potential ADSs 18,979 18,979 Diluted weighted average number of ADSs outstanding 21,531,330 21,531,330

Notes to reconciliation of our GAAP statements of income to our non-GAAP statements of income:

    (1). To exclude share-based compensation expenses from its non-GAAP
         measures primarily because they are non-cash expenses that the
         Company does not believe are reflective of ongoing operating results.
    (2). To exclude the impact caused by the impairment and disposal of
         available-for-sale securities, which is one-off in nature.



                          3SBio Inc. and subsidiaries
              Unaudited quarterly consolidated statements of income
     (expressed in thousands, except per share , per ADS and
'/>"/>
SOURCE  3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
Related medicine news :

1. 3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009
2. 3SBio Inc. Announces Unaudited First Quarter 2009 Results
3. 3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP
4. 3SBio Inc. Announces Filing of Annual Report on Form 20-F
5. 3SBio Inc. to Present at The CIBC World Markets 18th Annual Healthcare Conference
6. Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results
7. Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors
8. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
9. Leading Medical Developer Announces Plans for Texoma Medical Plaza
10. iMedX Announces Investment of $13M From RFE Investment Partners
11. Health Market Science Announces Commercial Release of CompleteSpend V2.5